Evidence from Rat Hepatocytes of an Unrecognized Pathway of 5-fluorouracil Metabolism with the Formation of a Glucuronide Derivative
Overview
Affiliations
Isolated rat hepatocytes in suspension were exposed to [3H]-5-fluorouracil for intervals over 2 h, following which the cells were removed from the media and sonicated, and the cytoplasm was sampled. High-performance liquid chromatography was used to separate 5-fluorouracil (FUra) from its known anabolites and catabolites, with subsequent quantitation of these metabolites by measurement of radioactivity. As the extracellular concentration of FUra was increased above 30 microM, the intracellular levels of FUra increased, with detection of a new peak of radioactivity distinct from any of the known anabolites or catabolites. This new metabolite, "G," increased in concentration as the extracellular concentration of FUra was raised above 1 mM. Inhibition of FUra catabolism by 2 mM thymine resulted in a further increase in intracellular FUra (approaching the extracellular FUra concentration) and was accompanied by a further increase in the intracellular concentration of "G," demonstrating that "G" was not formed via the catabolic pathway. The increase in intracellular FUra and "G" was not accompanied by an increase in intracellular anabolites, suggesting that "G" was formed via a novel metabolic pathway. "G" was retained within the hepatocytes, although it was not bound to intracellular macromolecules. "G" was converted to FUra in the presence of beta-D-glucuronidase; this reaction was inhibited with the addition of saccharo-1,4-beta-lactone, a specific inhibitor of the beta-D-glucuronidase. This data, together with evidence from hepatocyte homogenates in which formation of "G" was shown to be dependent on the concentration of uridine-5'-diphosphoglucuronic acid, demonstrates that "G" is a glucuronide of FUra. The formation of "G" suggests that FUra is metabolized via a previously unrecognized metabolic pathway.
Sweeny D, Barnes S, Heggie G, Diasio R Proc Natl Acad Sci U S A. 1987; 84(15):5439-43.
PMID: 3110788 PMC: 298873. DOI: 10.1073/pnas.84.15.5439.
Clinical pharmacology of 5-fluorouracil.
Diasio R, Harris B Clin Pharmacokinet. 1989; 16(4):215-37.
PMID: 2656050 DOI: 10.2165/00003088-198916040-00002.
A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients.
Coustere C, Mentre F, Sommadossi J, Diasio R, Steimer J Cancer Chemother Pharmacol. 1991; 28(2):123-9.
PMID: 2060083 DOI: 10.1007/BF00689701.
Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.
Schmittgen T, Webb T, Rosol T, Au J Cancer Chemother Pharmacol. 1992; 30(1):25-30.
PMID: 1586977 DOI: 10.1007/BF00686481.